Jokic et al. Dose Response, 2022

Jokic V, Savic-Vujovic K, Spasic J, Bukumiric Z, Marinkovic M, Radosavljevic D, Cavic M. Evaluation of Clinical and Genetic Determinants of Treatment Outcome in EGFR Mutation Positive Advanced Lung Adenocarcinoma. Dose Response, 2022 Aug 4;20(3):15593258221117354. doi: 10.1177/15593258221117354.

Like this article?

Leave a comment

Latest posts

Tanić et al. Nature Biotechnology 2022

M Tanić, I. Moghul, S. Rodney, P. Dhami, H. Vaikkinen, J. Ambrose, J. Barrett, A. Feber, S. Beck. Performance comparison and in-silico harmonisation of commercial platforms for DNA methylome analysis by targeted bisulfite sequencing. Nature Biotechnology 2022. https://doi.org/10.1038/s41587-022-01336-9

July 3, 2023

Cavic et al. Oncology, 2022

Cavic M, Kovacevic T, Zaric B, Stojiljkovic D, Jovanovic Korda N, Rancic M, Jankovic R, Radosavljevic D, Stojanovic G, Spasic J. Lung Cancer in Serbia. Journal of Thoracic Oncology. 2022, 17(7): 867-872. https://doi.org/10.1016/j.jtho.2022.04.010

July 3, 2023

Jokic et al. Expert Review of Anticancer Therapy, 2021

Jokic V, Savic-Vujovic K, Spasic J, Marinkovic M, Stanic N, Radosavljevic D, Cavic M. Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. Expert Review of Anticancer Therapy. 2021. https://www.tandfonline.com/doi/full/10.1080/14737140.2021.1893694

July 3, 2023

Marinkovic M et al. Biomed Research International, 2022

Marinkovic M, Popovic M, Stojanovic-Rundic S, Nikolic M, Cavic M, Gavrilovic D, Teodorovic D, Mitrovic D, Mijatovic Teodorovic Lj. Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients. Biomed Research International. 2022, 2022:7943609. https://doi.org/10.1155/2022/7943609.  

July 3, 2023

Jokic et al. Dose Response, 2022

Jokic V, Savic-Vujovic K, Spasic J, Bukumiric Z, Marinkovic M, Radosavljevic D, Cavic M. Evaluation of Clinical and Genetic Determinants of Treatment Outcome in EGFR Mutation Positive Advanced Lung Adenocarcinoma. Dose Response, 2022 Aug 4;20(3):15593258221117354. doi: 10.1177/15593258221117354.

July 3, 2023
Press

Participation at the IASLC 2022 WCLC World Conference on Lung Cancer

TRACEPIGEN participant Milena Cavic attended the World Lung Cancer Congress (WCLC22) organized by the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria, August 5-9, 2022. WCLC22 is traditionally the world’s largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. The congress covered a

August 24, 2022
Scroll to Top